SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.

Andrew C. McCreary,Jeffrey C. Glennon,Charles R. Ashby,Herbert Y. Meltzer,Zhu Li,Jan Hendrik Reinders,Mayke B. Hesselink,Stephen K. Long,A.H.J. Herremans,Herman H. van Stuivenberg,Rolf W. Feenstra,Chris G. Kruse

SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.

2007

Andrew C. McCreary
Jeffrey C. Glennon
Charles R. Ashby
Herbert Y. Meltzer
Zhu Li
Jan Hendrik Reinders
Mayke B. Hesselink
Stephen K. Long
A.H.J. Herremans
Herman H. van Stuivenberg
Rolf W. Feenstra
Chris G. Kruse

SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D 2 Receptor Antagonist and 5-HT 1A Receptor Agonist Potential Antipsychotic Drug

Keywords:

Partial agonist
Receptor antagonist
Anesthesia
Endogenous agonist
Antagonist
Endocrinology
Psychology
Internal medicine
Agonist
5-HT1A receptor
Competitive antagonist
Pharmacology
Dopamine receptor D2

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations